甲状腺过氧化物酶抗体与复发性流产女性活产率的前瞻性队列研究
该队列纳入2011至2017年哥本哈根大学医院825例连续复发性流产女性,其中454例为不明原因复发性流产。甲状腺过氧化物酶抗体(TPOAb)阳性与首胎活产率降低相关,T4治疗可提高活产率,但需随机对照试验确认。
要点
- 不明原因复发性流产女性中TPOAb阳性与活产率降低相关。
- TPOAb阳性者接受T4治疗后活产率与TPOAb阴性未治疗者相似。
- 建议对不明原因复发性流产女性筛查TPOAb作为风险因素。
核心结论
- 在不明原因复发性流产女性中,TPOAb阳性可预测活产率降低,但T4治疗可改善活产几率。
研究设计与样本
- 队列研究,纳入2011至2017年哥本哈根大学医院825例连续复发性流产女性,复发性流产定义为连续≥3次流产且排除抗磷脂综合征、父母染色体异常或子宫畸形。
主要发现
- 825例女性共有3246次既往流产,139例(16.8%)TPOAb阳性;TPOAb阳性与既往流产次数无关(p=0.41)。
- 不明原因复发性流产女性转诊后首次妊娠活产率为62.8%(285/454),TPOAb阳性者78/454(17.2%),其活产率降低(51.3% vs. 65.2%,p=0.02,aOR 0.2 [0.1-0.6],p=0.001)。
- T4治疗显著提高活产率(aOR 3.7 [1.4-9.8],p=0.007),TPOAb阳性接受T4者与TPOAb阴性未接受T4者活产率相似(p=0.70)。
- 仅30%的TPOAb阳性女性和39%妊娠期接受T4治疗的女性在转诊时已知有甲状腺疾病。
关键数值与推荐
- TPOAb阳性定义为≥60 kIU/L。
- 调整逻辑回归分析协变量包括:母亲年龄、TSH、既往流产次数、体重指数、吸烟、辅助生殖技术妊娠及甲状腺素替代治疗。
临床怎么用
- 建议对不明原因复发性流产女性筛查TPOAb以识别活产率降低的风险人群。
- TPOAb阳性者接受T4治疗可能改善活产率,但需随机对照试验确认。
- 生殖专家与内分泌科医生密切合作至关重要。
局限性
- T4治疗的有益效果需随机对照试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Thyroid autoimmunity has been associated with pregnancy loss. Suggested mechanisms include thyroid function aberrations or an underlying breach of immunotolerance. We hypothesized that thyroid autoimmunity is a marker of the latter in women with recurrent pregnancy loss. This study investigated thyroid peroxidase antibody (TPOAb) status as a predictor of live birth in women with unexplained recurrent pregnancy loss. Methods: Cohort study of 825 consecutive women with recurrent pregnancy loss followed at the tertiary referral center for Recurrent Pregnancy Loss, Copenhagen University Hospital (Rigshospitalet), from 2011 to 2017. Recurrent pregnancy loss was defined as ≥3 consecutive losses, and as unexplained by absence of antiphospholipid syndrome, parental chromosome abnormality, or uterus malformation. Upon first visit, all women were screened for thyrotropin (TSH) and TPOAbs (TPOAb positivity: ≥60 kIU/L). Adjusted logistic regression analyses included as covariates the following: maternal age, TSH, previous number of losses, body mass index, smoking, pregnancy achieved by assisted reproductive technology, and thyroxine replacement (T4) treatment. Results: We included 825 women with a total of 3246 previous losses, of whom 139 (16.8%) were TPOAb positive. TPOAb positivity was not associated with the previous number of losses (p = 0.41). Women with unexplained recurrent pregnancy loss had a live birth rate in the first pregnancy after referral of 62.8% (285 of 454). TPOAb positivity was found in 78 of 454 (17.2%) women and was associated with a reduced live birth rate (51.3% vs. 65.2%, p = 0.02, adjusted odds ratio [aOR] 0.2 [0.1-0.6] p = 0.001). Treatment with T4 increased live birth rate significantly (aOR 3.7 [1.4-9.8], p = 0.007), and TPOAb-positive women receiving T4 had a live birth rate similar to that of TPOAb-negative women not receiving T4 (p = 0.70). Only 30% of TPOAb-positive women and 39% of women treated with T4 during pregnancy had known thyroid disease at referral. Conclusion: In a large cohort of women with unexplained recurrent pregnancy loss, TPOAb positivity was predictive of a reduced live birth rate. However, T4 treatment improved odds of live birth. The study supports screening for TPOAbs as a risk factor in women with unexplained recurrent pregnancy loss. The beneficial effect of T4 treatment in this high-risk group needs confirmation by randomized controlled trials. Close collaboration between fertility experts and endocrinologists is paramount.
引用
- Bliddal S, Feldt-Rasmussen U, Rasmussen ÅK, et al. Thyroid Peroxidase Antibodies and Prospective Live Birth Rate: A Cohort Study of Women with Recurrent Pregnancy Loss. Thyroid. 2019. PMID: 31407629. doi:10.1089/thy.2019.0077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。